Denali Therapeutics (NASDAQ:DNLI) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Denali Therapeutics' stock has been given a "sell (D-)" rating by Weiss Ratings, while other brokerages maintain more optimistic views, with three analysts rating it as a Strong Buy and thirteen giving it a Buy rating.
• The stock price hit $15.96 with a low of $10.57 and a high of $33.33 in the last twelve months, and it currently has a market capitalization of $2.33 billion.
• Recent insider activity included two executives selling shares totaling approximately $39,884 each, indicating reduced personal stakes in the company.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Several other brokerages have also recently weighed in on DNLI. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Finally, Morgan Stanley reduced their price target on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a research report on Monday, August 18th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Denali Therapeutics presently has a consensus rating of "Buy" and an average price target of $33.50.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded up $0.08 during trading on Friday, hitting $15.96. The stock had a trading volume of 1,073,938 shares, compared to its average volume of 1,765,260. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -5.70 and a beta of 1.30. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $14.99 and a two-hundred day simple moving average of $14.47.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same period in the previous year, the firm earned ($0.59) EPS. On average, equities research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the sale, the insider owned 217,391 shares of the company's stock, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,680 shares of company stock valued at $91,569 over the last 90 days. Company insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Denali Therapeutics by 88.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock valued at $91,996,000 after purchasing an additional 3,184,042 shares during the last quarter. SCS Capital Management LLC acquired a new position in Denali Therapeutics in the 1st quarter valued at $2,692,000. TT International Asset Management LTD acquired a new position in Denali Therapeutics in the 2nd quarter valued at $909,000. Strs Ohio acquired a new position in Denali Therapeutics in the 1st quarter valued at $324,000. Finally, Millennium Management LLC raised its stake in Denali Therapeutics by 269.4% in the 1st quarter. Millennium Management LLC now owns 1,493,068 shares of the company's stock valued at $20,298,000 after purchasing an additional 1,088,844 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.